Kirby McInerney LLP is investigating potential claims against the Board
of Directors of KYTHERA Biopharmaceuticals, Inc. (“KYTHERA” or the
“Company”) (NASDAQ:KYTH) concerning the proposed acquisition of the
Company by Allergan plc (“Allergan”). Pursuant to the terms of the
definitive merger agreement, KYTHERA stockholders will have the right to
receive $75.00 in a combination of cash and shares of Allergan common
stock for each share of Kythera common stock they own, in a transaction
valued at approximately $2.1 billion.
The investigation concerns whether the KYTHERA Board of Directors
violated its fiduciary duties by agreeing to the proposed transaction
and whether the proposed consideration adequately values the Company’s
common stock.
If you are a KYTHERA stockholder and wish to obtain additional
information, please contact J. Brandon Walker, Esq. by email at bwalker@kmllp.com,
or telephone at (212) 699-1145 or toll free at (888) 529-4787, or by filling
out this contact form. There is no cost or obligation to you.
Kirby McInerney LLP is a New York-based law firm concentrating in
securities, whistleblower, antitrust and consumer litigation. For
additional information, please go to www.kmllp.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150617006481/en/
Copyright Business Wire 2015